Evidence map›Paper›PMID 36483546›Full record

ArticleFrontiers in immunology2022

Study on liver histopathology of chronic HBV infected patients with different normal ALT values.

Zhan Zeng, Hongxiao Hao, Xiaoyue Bi, Yanjie Lin, Liu Yang, Shiyu Wang, Ge Shen, Min Chang, Tingting Jiang, Wen Deng and 11 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Acute and Subacute Oral Toxicity Evaluation ofFood science & nutrition · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Zhan ZengDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Hongxiao HaoDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Xiaoyue BiDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Yanjie LinDepartment of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing, China.
Liu YangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Shiyu WangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Ge ShenDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Min ChangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Tingting JiangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Wen DengDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Huihui LuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Fangfang SunDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Yao LuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Yuanjiao GaoDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Ruyu LiuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Mengjiao XuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Xiaoxue ChenDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Leiping HuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Lu ZhangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Minghui LiDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Yao XieDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: Comparison of liver histopathological findings to explore the occurrence of liver inflammation in patients with chronic hepatitis B (CHB) under different alanine aminotransferase (ALT) normal values. Methods: The patients who were diagnosed as chronic hepatitis B virus (HBV) infection by liver histopathology at the Department of Pathology, Beijing Ditan Hospital due to clinical difficulty in defining the degree of liver inflammation or fibrosis were retrospectively enrolled from May 2008 to November 2020. Study of the incidence of significant hepatic histopathology in enrolled patients according to different ALT normal values. Using logistic regression to investigate the relevant factors of significant hepatic histopathology. Results: A total of 1474 patients were enrolled, 56.20% of the patients were male, and the overall patients' age was 36.80 ± 10.60 years. 39.00% of patients had liver inflammation grade G > 1, 34.70% liver fibrosis stage S > 1, and 48.17% patients had significant hepatic histopathology (G > 1 and/or S > 1). Among patients with normal ALT values, 36.40% and 40.40% had significant hepatic histopathology by American Association for the Study of Liver Diseases (AASLD) criteria and Chinese guideline criteria, respectively, but the difference was not statistically significant ( Conclusions: Our study found no statistically significant differences in the presence of significant hepatic histopathology under the two ALT criteria. ALT, HBsAg and HBeAg status were related to the occurrence of significant hepatic histopathology.

Indexed as

Hepatitis B, ChronicAdultFemaleHumansLiver CirrhosisMaleMiddle AgedRetrospective StudiesALT valuechronic HBV-infectionclinical indicatorsHBV therapyliver histopathology

Identifiers

PMID36483546
PMCPMC9725112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.